Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting

@inproceedings{Dent2016EvolocumabLL,
  title={Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting},
  author={Ricardo E Dent and Raju Joshi and C. Stephen Djedjos and Jason C. Legg and Mary Grace Elliott and Michelle L. Geller and Dawn Meyer and Ransi Somaratne and Chris P Recknor and Robert Jason Weiss},
  booktitle={SpringerPlus},
  year={2016}
}
Evolocumab has been shown to consistently reduce low-density lipoprotein cholesterol (LDL-C) across populations. The phase 3 studies included administration in the home-use and in-clinic settings but did not specifically evaluate the feasibility of home-use administration. Two clinical studies enrolled patients with hypercholesterolemia or mixed dyslipidemia on statin therapy and with/without ezetimibe received evolocumab in the home-use setting. Patients were randomized to self-administer… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.

References

Publications referenced by this paper.
Showing 1-10 of 17 references

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events

  • EA Stein, RP Giugliano, +11 authors MS Sabatine
  • N Engl J Med
  • 2015

Kynamro® (mipomersen sodium) prescribing information

  • Genzyme Corp
  • https://www.kynamro.com/~/media/Kynamro/Files…
  • 2015

Levemir ® ( insulin detemir [ rDNA origin ] ) injection prescribing information

  • FJ Raal, EA Stein, +13 authors D Gaudet
  • 2015

Praluent ® ( alirocumab ) prescribing information

  • JG Robinson, BS Nedergaard, +9 authors R Weiss
  • 2015

Similar Papers

Loading similar papers…